Soleus Capital Management L.P. Purchases Shares of 675,409 Septerna, Inc. (NASDAQ:SEPN)

Soleus Capital Management L.P. purchased a new position in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 675,409 shares of the company's stock, valued at approximately $15,467,000. Soleus Capital Management L.P. owned 1.52% of Septerna as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the company. Nuveen Asset Management LLC bought a new position in shares of Septerna in the fourth quarter worth $549,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Septerna in the fourth quarter worth $278,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Septerna in the fourth quarter worth $241,000. Janus Henderson Group PLC bought a new position in shares of Septerna in the fourth quarter worth $25,111,000. Finally, Deutsche Bank AG bought a new position in Septerna in the fourth quarter valued at $239,000.

Septerna Stock Down 3.1%

SEPN traded down $0.29 during trading on Friday, reaching $9.19. The stock had a trading volume of 372,784 shares, compared to its average volume of 714,643. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99. The business has a 50-day moving average of $6.73 and a 200-day moving average of $13.82.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million during the quarter. As a group, research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Septerna

In other Septerna news, Director Alan Ezekowitz purchased 7,491 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average cost of $6.35 per share, for a total transaction of $47,567.85. Following the completion of the transaction, the director now directly owns 24,911 shares in the company, valued at approximately $158,184.85. This represents a 43.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Gil M. Labrucherie purchased 6,282 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were acquired at an average price of $5.59 per share, with a total value of $35,116.38. Following the completion of the transaction, the chief financial officer now owns 36,282 shares of the company's stock, valued at approximately $202,816.38. This trade represents a 20.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 58,846 shares of company stock worth $352,565 over the last three months. Company insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on SEPN. Cantor Fitzgerald increased their target price on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Wells Fargo & Company increased their target price on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research note on Friday, May 16th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.